Sfoglia per AUTORE
RIVA M
Collezione ASL Biella

  

Items : 6

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9.

2023
ASL Biella
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Latagliata R; Zini G; D'Errigo MG; Bova I; Rizzo L; Riva M; Niscola P; Santini V; Breccia M; Giai V; Poloni A; Patriarca A; Crisà E; Capodanno I; Salutari P; Reda G; Cascavilla N; Ferrero D; Guarini A; Tripepi G; Iannì G; Russo E; Castelli A; Fattizzo B; Beltrami G; Bocchia M; Molteni A; Fenaux P; Germing U; et alii...

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
ASL Città di Torino
ASL Torino 4
AO Cuneo
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Della Porta MG; Naldi I; Santini V; Turrini M; Giordano L; Finelli C; Pasini P; Tosi P; Tanasi I; Selleri C; Frigeni M; Sancetta R; Norata M; Marchetti M; Grimaldi D; Fianchi L; Galimberti S; Ferrara F; Di Veroli A; Di Bona E; Occhini U; Rivoli G; Bono R; Calvisi A; Castelli A; Nicolino B; Leuzzi L; Molteni A; Guarini A; et alii...

Danazol Treatment for Thrombocytopenia in Myelodysplastic Syndromes: Can an "Old-fashioned" Drug be Effective? in HemaSphere / Hemasphere. 2023 Mar 27;7(4):e867. doi: 10.1097/HS9.0000000000000867. eCollection 2023 Apr.

2023
ASL Biella

Barcellini W; Molteni A; Cairoli R; Castelli A; Borin L; Lussana F; Ferrari S; Mazzon F; Rizzo L; Bosi A; Riva M; Fattizzo B;

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS) in Blood

2022
ASL Biella
ASL Torino 4

Lanino L; Salutari P; Perego A; Fattizzo B; Riva M; Ubezio M; Musto P; Cilloni D; Oliva EN; Voso MT; Pelizzari AM; Poloni A; Capodanno I; Elena C; Fozza C; Pane F; Breccia M; De Gobbi M; Di Bassiano F; Barraco D; Crisà E; Ferrero D; Frairia C; Vaccarino A; Griguolo D; Paolini S; Quintini M; Sessa M; Turrini M; et alii...

Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study in Blood

2022
ASL Biella

Bosi A; Fattizzo B; Rizzo L; Ferrari S; Lussana F; Borin LM; Castelli A; Bianchi P; Barcellini W; Cairoli R; Molteni A; Riva M;

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. in HemaSphere / Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. eCollection 2020 Oct.

2020
ASL Torino 5
ASL Biella
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
ASL Città di Torino
ASL Torino 4
AOU Alessandria
AOU Novara

Santini V; Tafuri A; Selleri C; Rivellini F; Secchi R; Sciumé M; Sarlo C; Riva M; Poloni A; Pilo F; Pelizzari A; Palumbo GA; Musto P; Oliva E; Messa E; Niscola P; Molteni A; Mancini S; Frattini F; Gaidano V; Guaragna G; Latagliata R; Gumenyuk S; Finelli C; Giai V; Fianchi L; Filì C; Ferrara IL; Fava C; et alii...